Skip to main content
Loading

Bionomics Ltd

February 27, 2024
CNS/Neurological
Bionomics Ltd
Bionomics, a publicly listed clinical late-stage company focused on addressing unmet needs in CNS. We are developing BNC-210, a Ph3-Ready First- and-Best-in-Class α-7 Nicotinic Receptor for the Treatment of Neuropsychiatric Disorders. BNC-210 has received Fast Trak designation for Post-Traumatic Stress Disorder (PTSD) and Social Anxiety Disorder (SAD).
Testimonials

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP